Additionally, clinical trials of FGF21-based drugs, such as pegbelfermin, LLF580, and BIO89-100, have been performed on patients with NAFLD/NASH, and great effects have been observed. Here, FGF21 is linked to metabolic dysfunction-associated steatohepatitis.